1. Home
  2. ZIM vs PBLS Comparison

ZIM vs PBLS Comparison

Compare ZIM & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ZIM Integrated Shipping Services Ltd.

ZIM

ZIM Integrated Shipping Services Ltd.

HOLD

Current Price

$23.93

Market Cap

3.1B

ML Signal

HOLD

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$30.34

Market Cap

3.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZIM
PBLS
Founded
1945
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.4B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
ZIM
PBLS
Price
$23.93
$30.34
Analyst Decision
Hold
Analyst Count
5
0
Target Price
$19.26
N/A
AVG Volume (30 Days)
1.2M
544.5K
Earning Date
05-20-2026
N/A
Dividend Yield
7.65%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.33
$25.56
52 Week High
$29.97
$33.65

Technical Indicators

Market Signals
Indicator
ZIM
PBLS
Relative Strength Index (RSI) 42.43 62.34
Support Level $22.93 $26.68
Resistance Level $24.05 $30.19
Average True Range (ATR) 0.73 2.45
MACD -0.13 0.29
Stochastic Oscillator 23.88 57.11

Price Performance

Historical Comparison
ZIM
PBLS

About ZIM ZIM Integrated Shipping Services Ltd.

ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: